TGTX·Nasdaq·US
TG Therapeutics
TG Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for B-cell malignancies and autoimmune diseases. Its revenue is currently dominated by BRIUMVI product sales in the United States.
Recent Activity
Updated Oct 24, 2026
–TG Therapeutics announced Phase 1 data for azer-cel in progressive multiple sclerosis in a late-breaking oral presentation at MSToronto2026.
–The data are described as the first reported clinical evaluation of an allogeneic CD19-directed CAR T-cell therapy in progressive MS and showed an encouraging preliminary safety profile.
Past updates are part of the Pro plan.
Thematic Position
Relationship Groups
Relationship details are part of the Pro plan.